Sal Patel, JD: Settlements That End Patent Litigation

May 23, 2018

Sal Patel, JD, partner at Schiff Hardin, LLP, explains why he expects to see more settlements between drug manufacturers in the future.


Recently, a biosimilar developer settled with AbbVie to end patent litigation over Humira. Do you think we’ll see more settlements like this in the future?

Absolutely. I think just as we see in Hatch-Waxman cases, I think there will be creative settlements that will be employed to end the uncertainty and the cost of the [Biologics Price Competition and Innovation Act, BPCIA] litigation, which I anticipate is going to be much higher than what we see with Hatch-Waxman litigation.

Related Content: